27th February 2018
The Generic and Biosimilar Medicines Association (GBMA), the peak body representing generic and biosimilar medicine suppliers in Australia, today announced the appointment of Ms Marnie Peterson as the new Chief Executive Officer of the organisation.
Ms Peterson has extensive experience in the generics industry and leadership roles both in commercial and marketing. She has led sales and marketing teams and is recognised for delivering plans aligned to strategic objectives, across local and international geographies. Throughout her career, she has built strong working relationships, as well as supporting and managing multiple stakeholders.
Ms Peterson will commence the role towards the end of March 2018.
“I’m delighted to welcome Marnie to the GBMA. Marnie has vast experience and a strong record of accomplishment in the generics sector, and actioning strategic objectives. The GBMA has a full agenda for 2018, and in the coming months we need to deliver the benefits to patients, and the generics and biosimilar sectors, identified as part of our strategic agreement extension negotiated in the May 2017 Federal Budget. Marnie is well placed to progress this exciting agenda and we are looking forward to her joining us towards the end of March.” said GBMA Chair Allan Tillack.
The GMBA is a representative body of generic and biosimilar medicine suppliers in Australia. Its members ensure that all Australians are offered the highest quality generic and biosimilar medicines in the world whilst providing affordable community health outcomes that benefit all Australians.
For more information, please contact the GBMA. www.gbma.com.au/about-gbma/contact-us/
–ENDS–
